drugset
drugset / Trial / NCT06751134

Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma

NCT06751134 ↗

Phase 1 Recruiting 12 enrolled Nanjing Children's Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with relapsed/refractory Neuroblastoma.

Timeline

Start
2024-12-28
Primary completion
2026-07-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CNK-UT Cell therapy 3e+07 cells/kg Intravenous
Subject CNK-UT Cell therapy 3.4e+08 cells/kg Intravenous

Indications

neuroblastoma